The assessments at a hearing on National Institutes of Health efforts to develop new tests came as officials aim to surpass 2 million tests a week by June. The NIH’s Rapid Acceleration of Diagnostics, or RADx, initiative aims to speed point-of-care tests to market by the end of the summer that could be used to regularly on returning workers, according to NIH Director Francis Collins.
More than 1,000 developers have already expressed interest in the program, and 79 have submitted full applications a little more than a week after it was launched — a response Collins said he has not seen in his 27 years at NIH.
One point-of-care test that has garnered attention from President Donald Trump is Abbott Laboratories’ 15-minute rapid test. Collins cautioned the product misses some infections, which he said is “a little bit of a knock on the Abbot test.” Another limitation is that there are only about 18,000 ID NOW machines that can process rapid tests, Collins said.
“To really be able to meet the need, that would have to go up substantially,” Collins said. He said another concern was the rapid test’s 15 percent false negative rate. „If you are in a circumstance where you really don’t want to miss a diagnosis from somebody already carrying the virus, you would like to have something that has a higher sensitivity than that,” he said.
Abbott spokesperson Darcy Ross told POLITICO Collins likely was referring to a Cleveland Clinic study that was conducted before the company discovered chemicals used to transport samples were interfering with test’s accuracy.
„We immediately communicated with our customers that they should use the direct swab method,“ Ross said. „When the direct swab method is used, the test is performing as expected and we are confident in its performance.“
Murray said at the hearing that innovative tests are only one piece of the puzzle, noting a supply chain under pressure must be addressed, too.
Source: politico.com
See more here: news365.stream
